CSPC Pharmaceutical Group Limited. EBIT

As of the most recent data (June 2026), CSPCY shows a EBIT of $13B. That compares with $7B in the prior-year period — up 90.9% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CSPCY's EBIT is now $13B (was $7B) — a 90.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether CSPC Pharmaceutical Group Limited. is outperforming or lagging.

The Healthcare sector average EBIT is about $23B. CSPC Pharmaceutical Group Limited. is at $13B, which is lower that average. That is roughly 42.2% below the sector mean. Use the comparison chart on this page to see how CSPCY stacks up against individual peers as well.

Tracking CSPCY's ebit over time shows whether CSPC Pharmaceutical Group Limited. is scaling, shrinking, or reshaping that part of the business. The current reading is $13B That compares with $7B in the prior-year period — up 90.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has CSPC Pharmaceutical Group Limited.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $13B) with ownership activity and broader fundamentals.